Komori
Inbound Platform Corp. (5587) · RiskRestated

Sharp Decline in PCR Testing Demand and Impairment of Related Software

First written in FY2023. 3 of 4 entries say "Restated". Latest entry: FY2025-H1.

4entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023 – FY2025-H12023: 12024: 220242025: 12025
Same theme, other companies
Decline in Testing Demand Due to COVID-19A theme 10 companies write about · 11 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2022: 5 of 8 companies on the "Worse" side.

3 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1RestatedAnnual report

    「During the current interim accounting period, there was no emergence of new business or other risks, nor any material change in the business or other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes in the risk associated with the sharp decline in demand for PCR testing and impairment of related software.
  2. FY2024-Q2RestatedAnnual report

    「During the cumulative second-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」

    The Company states that there have been no material changes in the risk associated with the sharp decline in demand for PCR testing and impairment of related software.
  3. FY2024-Q1RestatedAnnual report

    「During the six months ended [current first quarter], there was no emergence of new business or other risks, nor any material change in the business or other risks described in the annual securities report for the previous fiscal year.」

    The Company states that there have been no material changes in the risk associated with the sharp decline in demand for PCR testing and impairment of related software.
  4. FY2023First statedAnnual report

    「On the other hand, following the reclassification of COVID-19 to Category 5 under the Infectious Diseases Control Law, demand for PCR testing declined substantially from May 2023. As a result, the Company recorded an impairment loss, classified as an extraordinary loss, on software related to PCR testing referral services in its Life Media Tech business.」

    The disclosure describes an actual decline in demand for PCR testing referrals due to changes in the external environment and the recording of an impairment loss of ¥20,427 thousand during the fiscal year.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Inbound Platform Corp. yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Sharp Decline in PCR Testing Demand and Impairment of Related Software | Inbound Platform Corp. (5587) | Komori